Synedgen, Inc.
Synedgen develops first-in-class therapeutics that improve patient outcomes by promoting barrier function to repair mucosal injury, with their lead asset MIIST305 aimed at repairing GI mucosal injury.
Funding history
About Synedgen, Inc.
How much funding has Synedgen, Inc. raised?
Synedgen, Inc. has raised $1.8M in total funding.
Where is Synedgen, Inc. headquartered?
Synedgen, Inc. is headquartered in Claremont, CA.
What does Synedgen, Inc. do?
Synedgen develops first-in-class therapeutics that improve patient outcomes by promoting barrier function to repair mucosal injury, with their lead asset MIIST305 aimed at repairing GI mucosal injury.
What problem does Synedgen, Inc. solve?
Gastrointestinal mucosal injury leads to unchecked inflammation and tissue damage.
What's Synedgen, Inc.'s solution?
Synedgen develops first-in-class, orally delivered therapeutics — led by MIIST305 — that restore mucosal barrier function to repair GI injury.
What makes Synedgen, Inc. different?
The company points to targeted therapies, scalable GMP production, excellent safety profiles, and a strong IP position as what sets its regenerative therapeutics platform apart.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
